Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in
Closed
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverSTAA
HealthcareNGMUSD

STAAR Surgical Company

$22.47+0.4%
52w low $15.59$35.87 52w high
Market data · updated 20h ago
Market data
Market cap
$1.14B
52w range
$15.59 - $35.87
Beta
1.23
Sector
Healthcare
Data quality
83/100
Valuation
fair value estimate
$9.18
Margin of safety
-59.1%
Forward P/E
23.2x
PEG ratio
0.76
Quality & efficiency
Moat score
44/100
Return on equity
-6.0%
Profit margin
-7.2%
Debt / equity
0.11
Growth & analysts
Revenue growth
+119.6%
Analyst target
$30.00
Target upside
+33.5%
Analysts
8
Run the 10-point checklist before you buy How these numbers are made

About STAAR Surgical Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Valuation

ValueGrowthProfitHealthIncome42QUALITY
Overall Rating
27
Very low quality
Very low quality

Derived from filed metrics · High confidence (83% of the inputs available)

Moat Score44
Fair value estimate
$9.18-59.1% downside

Moat, fair value and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$1.14B
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
+119.6%
Profit Margin
-7.2%
ROE
-6.0%
Debt / Equity
0.11
Beta
1.23
High GrowthBeaten Down

Statistics

Similar Stocks · Healthcare

Latest News · STAA